Developer docs
API playgroundTry for free, no card

Search company profiles

Dewpoint Therapeutics

Full company profile

uuid00004aa

Namestring
Dewpoint Therapeutics
Legal namestring
Dewpoint Therapeutics, Inc.
Websiteurl
dewpointx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Dewpoint Therapeutics is a clinical-stage biotechnology company pioneering the application of biomolecular condensate biology to drug discovery. Founded in 2019 by Anthony Hyman (2022 Breakthrough Prize in Life Sciences), Richard Young (Whitehead Institute/MIT), and Phillip Sharp (1993 Nobel laureate, MIT), the company develops a new therapeutic modality called condensate-modulating drugs (c-mods) that correct aberrant condensates ("condensatopathies") underlying complex diseases. Operations span three sites: headquarters and labs in Boston (451 D Street), plus research operations in Dresden and Frankfurt, Germany, the latter co-located with co-founder Hyman's Max Planck Institute. Headcount is approximately 51–120 staff across the network. Targeted indications span oncology (gastric cancer, MYC-driven cancers), neurodegeneration (ALS, FTD), cardiopulmonary disease, metabolic disease, and virology (HPV).

The company's central technical asset is its proprietary AI-powered integrated drug discovery platform, ERSA (powered by the ERSAi engine), which combines nearly 3 petabytes of proprietary data, over 4 million condensate cell images, and a high-throughput condensate phenomics screening system with computer vision to identify c-mod candidates. The platform fuses multimodal data — condensate proteomics, genetics, and cellular phenotypic signatures — through in-house ERSA Computational Models that predict chemical perturbations and functional cellular outcomes. A proprietary condensate-focused compound library and selective-partitioning chemistry support lead optimization. The clinical-stage pipeline includes DPTX3186, a first-in-class oral c-mod targeting the oncogenic Wnt/β-catenin pathway (FDA Orphan Drug and Fast Track Designations, IND opened October 2025, first patient dosed February 2026), alongside preclinical development candidates for MYC-driven oncology and TDP-43 pathology in ALS.

Dewpoint operates a partner-centric business model in which it develops proprietary c-mods internally through Phase 1/2 trials while co-developing assets with major pharmaceutical companies — Bayer (cardiopulmonary), Novo Nordisk (metabolic), Mitsubishi Tanabe Pharma — leveraging their development and commercial capabilities. Anticipated future revenue derives from direct product sales, milestone payments, and royalties on licensed programs; near-term cash flow is supported by collaboration economics and equity capital rather than product revenue. To date the company has raised approximately $367 million across Series A through D equity rounds, with key institutional backers including SoftBank Vision Fund 2 (Series C lead), Polaris Partners, ARCH Venture Partners, Leaps by Bayer, and Samsara BioCapital, plus non-dilutive grant funding from the Bill & Melinda Gates Foundation for its HPV Viral Condensate Phenomics Atlas initiative.

Short descriptiontext

Dewpoint Therapeutics is a clinical-stage biotech developing condensate-modulating drugs (c-mods) that target previously undruggable disease biology. Its AI-powered ERSA platform addresses oncology, neurodegeneration, and metabolic diseases, with partnerships spanning Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
condensate-modulating drugs, biomolecular condensate biology, drug discovery platform, AI-powered therapeutics, clinical-stage biotechnology
Industry4 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Development & Licensing
TypeLicensing Royalties
Description

Developing proprietary c-mod therapeutics through clinical development with intent to commercialize directly or through licensing partnerships with pharmaceutical companies. Revenue will come from product sales and/or milestone/royalty payments from partners.

dewpointx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Dewpoint Therapeutics is a clinical-stage biotechnology company developing condensate-modulating drugs (c-mods), a novel class of small-molecule therapeutics that target dysregulated biomolecular condensates to treat complex diseases. The company combines its proprietary AI-powered ERSA drug discovery platform with high-throughput condensate phenomics to discover and develop drug candidates against previously undruggable targets such as MYC and β-catenin in oncology and TDP-43 in neurodegeneration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • DPTX3186 demonstrated tumor regressions in MYC-dependent models and favorable in vivo pharmacology
+2 more records
Product overview1 text field

Dewpoint Therapeutics is pioneering condensate biology to develop a new class of medicines called condensate-modulating drugs (c-mods). The company's integrated platform combines proprietary AI technology (ERSA/ERSAi) with high-throughput condensate phenomics for target identification and drug discovery. The core pipeline includes DPTX3186 (Wnt/β-catenin modulator for gastric cancer in clinical trials), MYC condensate modulator (oncology), and TDP-43 condensate modulator (ALS/neurodegeneration). Dewpoint also develops research tools including the CD-CODE condensate database and viral condensate phenomics atlas, while maintaining strategic partnerships with Bayer, Novo Nordisk, and Chemify.

Product and service4 records
1DPTX3186
CategoryDrug Candidate (Oncology)
Description

First-in-class oral condensate modulator (c-mod) targeting the oncogenic Wnt/β-catenin pathway for the treatment of gastric cancer and other Wnt-driven solid tumors. Received FDA Orphan Drug Designation (October 2025) and FDA Fast Track designation (November 2025), with IND opened (October 2025) and first patient dosed in the Phase 1a/2a trial in February 2026.

2MYC Condensate Modulator
CategoryDrug Candidate (Oncology)
Description

First-in-class small-molecule condensate modulator targeting MYC-driven oncogenic transcription in cancer cells. Development candidate selected in February 2026 with preclinical data demonstrating potency and selectivity in MYC-dependent cellular systems, favorable in vivo pharmacology including tumor regressions in MYC-dependent models, and tolerability supportive of IND-enabling studies.

3TDP-43 Condensate Modulator
CategoryDrug Candidate (Neurodegeneration)
Description

Small-molecule condensate-modulating drug (c-mod) targeting TDP-43 condensatopathy for the treatment of ALS and related neurodegenerative diseases, including FTD, Perry Syndrome, CTE, and Inclusion Body Myositis. Development candidate nominated in January 2026.

4Condensate-Modulating Drugs (c-mods)
CategoryTherapeutic Modality
Description

Novel therapeutic modality in which small molecules modulate the formation, composition, or dissolution of biomolecular condensates to treat condensatopathies. C-mods can target previously undruggable proteins and pathways by targeting the condensate environment rather than individual protein active sites.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration for developing condensate-modulating therapeutics in cardiopulmonary diseases. Bayer is a key partner providing pharmaceutical development expertise and resources alongside Dewpoint's condensate biology platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration for developing condensate-modulating therapeutics in metabolic diseases. Novo Nordisk brings global pharmaceutical capabilities and development expertise for metabolic disease programs.

3Mitsubishi Tanabe Pharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration to advance therapeutic programs leveraging Dewpoint's condensate biology platform in specific disease areas.

globenewswire.com
Strategic tierSupportingTypeTechnology or Integration
Description

Partnership to develop digitally discovered and automatically synthesized novel molecules against condensate targets in Dewpoint's oncology and neurodegeneration pipeline. Chemify contributes chemistry AI and automation technology platform.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Partnership through Evotec's INDiGO platform providing integrated preclinical, regulatory, and CMC support for DPTX3186 development candidate to advance into clinical development.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic partnership with the institute where co-founder Tony Hyman serves as Director and Group Leader. Strong academic ties supporting condensate science research.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic partnership with MIT where co-founders Rick Young and Phillip Sharp are faculty members. Partnership supports condensate biology research and talent development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Closest peer: also founded by Dewpoint co-founder Richard Young, CAMP4 is developing RNA-based therapeutics that target gene regulatory condensates. Directly comparable in modality (condensate biology), stage, and founder network.

TypeDirect peer
Description

Clinical-stage precision medicine company using motion-based computational drug discovery (Helix platform) against challenging oncology targets. Comparable as a platform-driven biotech targeting previously undruggable proteins with sophisticated computational approaches.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput phenotypic screening with machine learning. Comparable as a platform biotech using proprietary data, imaging, and AI to power target ID and lead optimization at scale.

TypeDirect peer
Description

Operates a computational drug discovery platform used internally and through partnerships to advance small molecule programs. Comparable as a platform biotech leveraging proprietary physics-based/AI methods to enable drug discovery across pharma partners.

TypeDirect peer
Description

Machine learning-driven drug discovery company combining high-throughput biology with ML models. Comparable as an AI-first platform biotech using proprietary data generation (cellular imaging, omics) and ML for target ID and lead optimization.

6Syros Pharmaceuticals
TypeDirect peer
Description

Gene regulation company co-founded by Dewpoint co-founder Richard Young, focused on controlling expression of disease-driving genes. Comparable in gene-control biology and through shared founder network, though Syros targets transcriptional machinery more directly.

TypeBroad incumbent
Description

Co-founded by Dewpoint co-founder Phillip Sharp; pioneer in RNAi therapeutics now commercial-stage. Comparable as a long-tenured biotech with shared scientific founder lineage, though it operates in a different therapeutic modality.

TypeEmerging player
Description

AI-driven drug discovery company using generative models and physics to design small molecules. Comparable as an emerging AI-platform biotech competing for similar pharma partnerships and talent in next-generation computational discovery.

9Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-backed AI drug discovery company with deep resources and pharma partnerships. Comparable as a well-funded AI-first platform biotech operating across multiple therapeutic areas with major pharma partners.

TypeEmerging player
Description

AI-driven small molecule design company using structure-based deep learning for hit identification across pharma partnerships. Comparable as a smaller AI-platform competitor pursuing similar pharma collaboration economics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dewpoint Therapeutics

Biopharmaceuticalsdewpointx.com

Dewpoint Therapeutics is a clinical-stage biotech developing condensate-modulating drugs (c-mods) that target previously undruggable disease biology. Its AI-powered ERSA platform addresses oncology, neurodegeneration, and metabolic diseases, with partnerships spanning Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma.

What Dewpoint Therapeutics does

Dewpoint Therapeutics is a clinical-stage biotechnology company pioneering the application of biomolecular condensate biology to drug discovery. Founded in 2019 by Anthony Hyman (2022 Breakthrough Prize in Life Sciences), Richard Young (Whitehead Institute/MIT), and Phillip Sharp (1993 Nobel laureate, MIT), the company develops a new therapeutic modality called condensate-modulating drugs (c-mods) that correct aberrant condensates ("condensatopathies") underlying complex diseases. Operations span three sites: headquarters and labs in Boston (451 D Street), plus research operations in Dresden and Frankfurt, Germany, the latter co-located with co-founder Hyman's Max Planck Institute. Headcount is approximately 51–120 staff across the network. Targeted indications span oncology (gastric cancer, MYC-driven cancers), neurodegeneration (ALS, FTD), cardiopulmonary disease, metabolic disease, and virology (HPV).

The company's central technical asset is its proprietary AI-powered integrated drug discovery platform, ERSA (powered by the ERSAi engine), which combines nearly 3 petabytes of proprietary data, over 4 million condensate cell images, and a high-throughput condensate phenomics screening system with computer vision to identify c-mod candidates. The platform fuses multimodal data — condensate proteomics, genetics, and cellular phenotypic signatures — through in-house ERSA Computational Models that predict chemical perturbations and functional cellular outcomes. A proprietary condensate-focused compound library and selective-partitioning chemistry support lead optimization. The clinical-stage pipeline includes DPTX3186, a first-in-class oral c-mod targeting the oncogenic Wnt/β-catenin pathway (FDA Orphan Drug and Fast Track Designations, IND opened October 2025, first patient dosed February 2026), alongside preclinical development candidates for MYC-driven oncology and TDP-43 pathology in ALS.

Dewpoint operates a partner-centric business model in which it develops proprietary c-mods internally through Phase 1/2 trials while co-developing assets with major pharmaceutical companies — Bayer (cardiopulmonary), Novo Nordisk (metabolic), Mitsubishi Tanabe Pharma — leveraging their development and commercial capabilities. Anticipated future revenue derives from direct product sales, milestone payments, and royalties on licensed programs; near-term cash flow is supported by collaboration economics and equity capital rather than product revenue. To date the company has raised approximately $367 million across Series A through D equity rounds, with key institutional backers including SoftBank Vision Fund 2 (Series C lead), Polaris Partners, ARCH Venture Partners, Leaps by Bayer, and Samsara BioCapital, plus non-dilutive grant funding from the Bill & Melinda Gates Foundation for its HPV Viral Condensate Phenomics Atlas initiative.

Dewpoint Therapeutics firmographics

Firmographics
Name
Dewpoint Therapeutics
Legal name
Dewpoint Therapeutics, Inc.
Website
https://dewpointx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Dewpoint Therapeutics is a clinical-stage biotech developing condensate-modulating drugs (c-mods) that target previously undruggable disease biology. Its AI-powered ERSA platform addresses oncology, neurodegeneration, and metabolic diseases, with partnerships spanning Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma.
Ownership category
akta.pro rank

Dewpoint Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Condensate-modulating drugs
  • Biomolecular condensate biology
  • Drug discovery platform
  • AI-powered therapeutics
  • Clinical-stage biotechnology

Where Dewpoint Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Dewpoint Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Therapeutic Development & Licensing: Developing proprietary c-mod therapeutics through clinical development with intent to commercialize directly or through licensing partnerships with pharmaceutical companies. Revenue will come from product sales and/or milestone/royalty payments from partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Dewpoint Therapeutics product offering

Product offering

Core offering

Dewpoint Therapeutics is a clinical-stage biotechnology company developing condensate-modulating drugs (c-mods), a novel class of small-molecule therapeutics that target dysregulated biomolecular condensates to treat complex diseases. The company combines its proprietary AI-powered ERSA drug discovery platform with high-throughput condensate phenomics to discover and develop drug candidates against previously undruggable targets such as MYC and β-catenin in oncology and TDP-43 in neurodegeneration.

Product overview

Dewpoint Therapeutics is pioneering condensate biology to develop a new class of medicines called condensate-modulating drugs (c-mods). The company's integrated platform combines proprietary AI technology (ERSA/ERSAi) with high-throughput condensate phenomics for target identification and drug discovery. The core pipeline includes DPTX3186 (Wnt/β-catenin modulator for gastric cancer in clinical trials), MYC condensate modulator (oncology), and TDP-43 condensate modulator (ALS/neurodegeneration). Dewpoint also develops research tools including the CD-CODE condensate database and viral condensate phenomics atlas, while maintaining strategic partnerships with Bayer, Novo Nordisk, and Chemify.

Differentiator

Problem solved

Functional benefit

Products and services

  • DPTX3186 First-in-class oral condensate modulator (c-mod) targeting the oncogenic Wnt/β-catenin pathway for the treatment of gastric cancer and other Wnt-driven solid tumors. Received FDA Orphan Drug Designation (October 2025) and FDA Fast Track designation (November 2025), with IND opened (October 2025) and first patient dosed in the Phase 1a/2a trial in February 2026.
  • MYC Condensate Modulator First-in-class small-molecule condensate modulator targeting MYC-driven oncogenic transcription in cancer cells. Development candidate selected in February 2026 with preclinical data demonstrating potency and selectivity in MYC-dependent cellular systems, favorable in vivo pharmacology including tumor regressions in MYC-dependent models, and tolerability supportive of IND-enabling studies.
  • TDP-43 Condensate Modulator Small-molecule condensate-modulating drug (c-mod) targeting TDP-43 condensatopathy for the treatment of ALS and related neurodegenerative diseases, including FTD, Perry Syndrome, CTE, and Inclusion Body Myositis. Development candidate nominated in January 2026.
  • Condensate-Modulating Drugs (c-mods) Novel therapeutic modality in which small molecules modulate the formation, composition, or dissolution of biomolecular condensates to treat condensatopathies. C-mods can target previously undruggable proteins and pathways by targeting the condensate environment rather than individual protein active sites.

Quantifiable outcome

  • DPTX3186 demonstrated tumor regressions in MYC-dependent models and favorable in vivo pharmacology
  • +2 more outcomes

Companies that use Dewpoint Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Dewpoint Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Dewpoint Therapeutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and supporting.

  • BayercoreStrategic or Co-development PartnerStrategic collaboration for developing condensate-modulating therapeutics in cardiopulmonary diseases. Bayer is a key partner providing pharmaceutical development expertise and resources alongside Dewpoint's condensate biology platform.
  • Novo NordiskcoreStrategic or Co-development PartnerStrategic collaboration for developing condensate-modulating therapeutics in metabolic diseases. Novo Nordisk brings global pharmaceutical capabilities and development expertise for metabolic disease programs.
  • Mitsubishi Tanabe PharmacoreStrategic or Co-development PartnerCollaboration to advance therapeutic programs leveraging Dewpoint's condensate biology platform in specific disease areas.
  • ChemifysupportingTechnology or IntegrationPartnership to develop digitally discovered and automatically synthesized novel molecules against condensate targets in Dewpoint's oncology and neurodegeneration pipeline. Chemify contributes chemistry AI and automation technology platform.
  • EvotecsupportingStrategic or Co-development PartnerPartnership through Evotec's INDiGO platform providing integrated preclinical, regulatory, and CMC support for DPTX3186 development candidate to advance into clinical development.
  • Max Planck Institute (MPI-CBG)supportingStrategic or Co-development PartnerAcademic partnership with the institute where co-founder Tony Hyman serves as Director and Group Leader. Strong academic ties supporting condensate science research.
  • MIT (Massachusetts Institute of Technology)supportingStrategic or Co-development PartnerAcademic partnership with MIT where co-founders Rick Young and Phillip Sharp are faculty members. Partnership supports condensate biology research and talent development.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Dewpoint Therapeutics competitors and assessment

Company assessment

Direct peers

  • CAMP4 Therapeutics: Closest peer: also founded by Dewpoint co-founder Richard Young, CAMP4 is developing RNA-based therapeutics that target gene regulatory condensates. Directly comparable in modality (condensate biology), stage, and founder network.
  • Relay Therapeutics: Clinical-stage precision medicine company using motion-based computational drug discovery (Helix platform) against challenging oncology targets. Comparable as a platform-driven biotech targeting previously undruggable proteins with sophisticated computational approaches.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput phenotypic screening with machine learning. Comparable as a platform biotech using proprietary data, imaging, and AI to power target ID and lead optimization at scale.
  • Schrödinger, Inc. Operates a computational drug discovery platform used internally and through partnerships to advance small molecule programs. Comparable as a platform biotech leveraging proprietary physics-based/AI methods to enable drug discovery across pharma partners.
  • Insitro: Machine learning-driven drug discovery company combining high-throughput biology with ML models. Comparable as an AI-first platform biotech using proprietary data generation (cellular imaging, omics) and ML for target ID and lead optimization.
  • Syros Pharmaceuticals: Gene regulation company co-founded by Dewpoint co-founder Richard Young, focused on controlling expression of disease-driving genes. Comparable in gene-control biology and through shared founder network, though Syros targets transcriptional machinery more directly.

Broad incumbents

  • Alnylam Pharmaceuticals: Co-founded by Dewpoint co-founder Phillip Sharp; pioneer in RNAi therapeutics now commercial-stage. Comparable as a long-tenured biotech with shared scientific founder lineage, though it operates in a different therapeutic modality.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company with deep resources and pharma partnerships. Comparable as a well-funded AI-first platform biotech operating across multiple therapeutic areas with major pharma partners.

Emerging players

  • Genesis Therapeutics: AI-driven drug discovery company using generative models and physics to design small molecules. Comparable as an emerging AI-platform biotech competing for similar pharma partnerships and talent in next-generation computational discovery.
  • Atomwise: AI-driven small molecule design company using structure-based deep learning for hit identification across pharma partnerships. Comparable as a smaller AI-platform competitor pursuing similar pharma collaboration economics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Dewpoint Therapeutics social profiles

Digital presence

Dewpoint Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dewpoint Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Dewpoint Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dewpoint Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dewpoint Therapeutics

What does Dewpoint Therapeutics do?

Dewpoint Therapeutics is a clinical-stage biotechnology company developing condensate-modulating drugs (c-mods), a novel class of small-molecule therapeutics that target dysregulated biomolecular condensates to treat complex diseases. The company combines its proprietary AI-powered ERSA drug discovery platform with high-throughput condensate phenomics to discover and develop drug candidates against previously undruggable targets such as MYC and β-catenin in oncology and TDP-43 in neurodegeneration.

Is Dewpoint Therapeutics a public or private company?

Dewpoint Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Dewpoint Therapeutics founded?

Dewpoint Therapeutics was founded in 2019. It employs 51 to 100 people.

Where is Dewpoint Therapeutics based?

Dewpoint Therapeutics is headquartered in Boston, United States, in the North America region.

How does Dewpoint Therapeutics make money?

One revenue line is on record: therapeutic Development & Licensing.

Who are Dewpoint Therapeutics's main competitors?

Direct peers on record are CAMP4 Therapeutics, Relay Therapeutics, Recursion Pharmaceuticals, Schrödinger, Inc., Insitro and Syros Pharmaceuticals. Broad incumbents are Alnylam Pharmaceuticals and Isomorphic Labs. Emerging players are Genesis Therapeutics and Atomwise.

Does Dewpoint Therapeutics have an API?

No public API is recorded for Dewpoint Therapeutics.

What industry is Dewpoint Therapeutics in?

Dewpoint Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeCancer Research UK and Dewpoint Therapeutics Advance DPTX8743 into Phase 1/2a Trial for MYC-Driven Cancers | DWPT Stock NewsCancer Research UK and Dewpoint Therapeutics announced a collaboration to advance DPTX8743, a small molecule targeting MYC condensates, into a Phase 1/2a clinical trial. Cancer Research UK's Centre for Drug Development will fund and execute the trial, while Dewpoint retains all rights to the drug. The trial aims to evaluate safety and clinical effectiveness in MYC-driven cancers such as ovarian, colorectal, and pancreatic.FinancialContent Business PageCancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical developmentCancer Research UK and Dewpoint Therapeutics announced a collaboration to advance DPTX8743, a MYC condensate modulator, into clinical development. Cancer Research UK will fund and execute a Phase 1/2a trial, while Dewpoint retains all rights and can license results. The partnership aims to evaluate safety and clinical proof of concept for MYC-driven cancers.Stock TitanDewpoint Therapeutics partners for Phase 1/2a cancer trialCancer Research UK and Dewpoint Therapeutics announced a collaboration to advance DPTX8743, a MYC condensate modulator, into clinical development. Cancer Research UK will fund and execute a Phase 1/2a trial, while Dewpoint retains all rights and can license results. The trial aims to evaluate safety and proof of concept in MYC-driven cancers.GlobeNewswireCancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical developmentCancer Research UK and Dewpoint Therapeutics announced a collaboration to advance DPTX8743, a MYC condensate modulator, into clinical development. Cancer Research UK will fund and execute a Phase 1/2a trial, while Dewpoint retains all rights and can license results. The partnership aims to evaluate safety and clinical proof of concept for MYC-driven cancers.TradingViewCancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical developmentCancer Research UK and Dewpoint Therapeutics announced a collaboration to advance DPTX8743, a MYC condensate modulator, into clinical development. Cancer Research UK will fund and execute a Phase 1/2a trial, while Dewpoint retains all rights and can license results. The partnership aims to evaluate safety and proof of concept for MYC-driven cancers.TradingViewDewpoint Therapeutics Advances DPTX8743 to a Funded Phase 1/2a TrialCancer Research UK will fund, sponsor, and execute a Phase 1/2a trial of Dewpoint Therapeutics' DPTX8743, including CTA-enabling studies. Dewpoint retains all rights to the candidate, while Cancer Research UK is eligible for downstream milestones and royalties. The collaboration aims to evaluate safety and establish clinical proof of concept for MYC-driven cancers.BioWorldDewpoint and Novo partner on diabetes drugs targeting biomolecular condensatesDewpoint Therapeutics and Novo Nordisk signed a $745 million deal for two small-molecule programs targeting biomolecular condensates in diabetes. The partnership combines Novo's metabolic expertise with Dewpoint's AI discovery engine to find drugs for insulin sensitivity and resistance.BioWorldDewpoint Therapeutics discovers new β-catenin modulatorsDewpoint Therapeutics Inc. has patented new β-catenin (CTNNB1) condensate modulators, which the company says are potentially useful for cancer treatment. The patent was filed on May 13, 2026, and the company has not disclosed further details.GlobeNewswireDewpoint Therapeutics Reports Preclinical Data on Oral MYC Condensate Modulator at AACR 2026Dewpoint Therapeutics presented preclinical data at AACR 2026 on its oral MYC condensate modulator, which disrupted MYC condensates and reduced MYC-driven gene expression. The compound showed tumor regression and stasis in solid tumor models with a favorable tolerability profile. The company sees potential for translation into therapeutic impact for patients.BioSpaceDewpoint Therapeutics Reports Preclinical Data on Oral MYC Condensate Modulator at AACR 2026Dewpoint Therapeutics presented preclinical data at AACR 2026 on its oral MYC condensate modulator, which reduced MYC condensates and inhibited MYC-driven cancer cell growth. The compound showed tumor regression and stasis in solid tumor models with a favorable tolerability profile. The company sees potential for translation into therapeutic impact for patients.